Inflation, Biosimilars, And The Wizard Of Oz: An Interview With Teva’s Christine Baeder
The new chair of the US generics association talks to the Pink Sheet about how to make sure that policymakers don’t take the industry for granted.
You may also be interested in...
All Carrots, No Sticks: House Republican Drug Shortage Plan Ups Reimbursement But Lacks Supply, Quality Commitments
New Republican House Energy and Commerce shortage plan is seen as reasonable starting point, though in need of much strength to address root causes of supply troubles. Most changes apply to generic drugs, but a few could impact brands.
Vaccine makers get all the credit (among those who think any credit is due) for ending the pandemic, but generic sponsors want to remind policymakers that their plants stayed open during the worst of COVID-19 to ensure that hospitals were stocked and medicines for chronic conditions didn’t run short.
The market has responded to Teva’s newly released 2023 financial guidance, with lingering questions over its ability to hit its forecasts amid a continued dearth of complex generics and further investments in Teva’s pipeline.